Literature DB >> 28857256

Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.

Jessica D Hathaway-Schrader1, Bently P Doonan1, Azim Hossain1, Faisal F Y Radwan1, Lixia Zhang1, Azizul Haque1.   

Abstract

Melanoma represents an ever-increasing problem in the western world as incidence rates continue to climb. Though manageable during early stages, late stage metastatic disease is highly resistant to current intervention. We have previously shown that gamma-interferon-inducible lysosomal thiol-reductase (GILT) enhances HLA class II antigen processing and immune detection of human melanoma cells. Here we report that GILT expression inhibits a potential target, paired box-3 (PAX-3) protein, in late stage human metastatic melanoma. We also show that GILT transfection or induction by IFN-γ, decreases PAX-3 protein expression while upregulating the expression of Daxx, which is also a repressor of PAX-3. Confocal microscopic analysis demonstrated that GILT co-localizes with PAX-3 protein, but not with Daxx within melanoma cells. Immunoprecipitation and immunoblotting studies suggest that GILT expression negatively regulates PAX-3 through the autophagy pathway, potentially resulting in increased susceptibility to conventional treatment in the form of chemotherapy or radiotherapy. While high-dose radiation is a common treatment for melanoma patients, our data suggest that GILT expression significantly increased the susceptibility of melanoma cells to low-dose radiation therapy via upregulation of tumor suppressor protein p53. Overall, these data suggest that GILT has multiple roles in inducing human melanoma cells as better targets for radiation and immunotherapy.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  DAXX; GILT; PAX-3; autophagy; melanoma; radiation

Mesh:

Substances:

Year:  2017        PMID: 28857256      PMCID: PMC5747991          DOI: 10.1002/jcb.26383

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  41 in total

1.  PAX3 is expressed in human melanomas and contributes to tumor cell survival.

Authors:  F A Scholl; J Kamarashev; O V Murmann; R Geertsen; R Dummer; B W Schäfer
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

2.  Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT).

Authors:  B Arunachalam; U T Phan; H J Geuze; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.

Authors:  Kazuo Koyanagi; Christine Kuo; Taku Nakagawa; Takuji Mori; Hideaki Ueno; Arnulfo R Lorico; He-Jing Wang; Eddie Hseuh; Steven J O'Day; Dave S B Hoon
Journal:  Clin Chem       Date:  2005-04-07       Impact factor: 8.327

4.  Functional requirements for the lysosomal thiol reductase GILT in MHC class II-restricted antigen processing.

Authors:  K Taraszka Hastings; Rebecca L Lackman; Peter Cresswell
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

5.  Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity.

Authors:  Shu-Jie He; Graham Stevens; Antony W Braithwaite; Michael R Eccles
Journal:  Mol Cancer Ther       Date:  2005-06       Impact factor: 6.261

6.  Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients.

Authors:  Eiji Kiyohara; Keisuke Hata; Stella Lam; Dave S B Hoon
Journal:  Methods Mol Biol       Date:  2014

7.  EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes.

Authors:  R Li; H Pei; D K Watson; T S Papas
Journal:  Oncogene       Date:  2000-02-10       Impact factor: 9.867

8.  Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma.

Authors:  Oliver G Goldstein; Laela M Hajiaghamohseni; Shereen Amria; Kumaran Sundaram; Sakamuri V Reddy; Azizul Haque
Journal:  Cancer Immunol Immunother       Date:  2008-03-15       Impact factor: 6.968

9.  A genomic screen identifies TYRO3 as a MITF regulator in melanoma.

Authors:  Shoutian Zhu; Heiko Wurdak; Yan Wang; Anna Galkin; Haiyan Tao; Jie Li; Costas A Lyssiotis; Feng Yan; Buu P Tu; Loren Miraglia; John Walker; Fanxiang Sun; Anthony Orth; Peter G Schultz; Xu Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

10.  PAX3 and ETS1 synergistically activate MET expression in melanoma cells.

Authors:  J D Kubic; E C Little; J W Lui; T Iizuka; D Lang
Journal:  Oncogene       Date:  2014-12-22       Impact factor: 9.867

View more
  7 in total

1.  IFI30 expression predicts patient prognosis in breast cancer and dictates breast cancer cells proliferation via regulating autophagy.

Authors:  Yan Fan; Xu Wang; Yang Li
Journal:  Int J Med Sci       Date:  2021-07-25       Impact factor: 3.738

2.  Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.

Authors:  Benjamin M Johnson; Faisal F Y Radwan; Azim Hossain; Bently P Doonan; Jessica D Hathaway-Schrader; Jason M God; Christina V Voelkel-Johnson; Narendra L Banik; Sakamuri V Reddy; Azizul Haque
Journal:  J Cell Biochem       Date:  2018-10-30       Impact factor: 4.429

3.  Overexpressed VEPH1 inhibits epithelial-mesenchymal transition, invasion, and migration of human cutaneous melanoma cells through inactivating the TGF-β signaling pathway.

Authors:  Hao Feng; Xiao-Min Jia; Ni-Na Gao; Hua Tang; Wei Huang; Ning Ning
Journal:  Cell Cycle       Date:  2019-09-04       Impact factor: 4.534

4.  PAX3 is a biomarker and prognostic factor in melanoma: Database mining.

Authors:  Yong Liu; Shengnan Cui; Wenbin Li; Yiding Zhao; Xiaoning Yan; Jianqin Xu
Journal:  Oncol Lett       Date:  2019-03-18       Impact factor: 2.967

5.  GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.

Authors:  Jessica D Hathaway-Schrader; Duncan Norton; Katherine Hastings; Bently P Doonan; Shaun Tompkins Fritz; Jennifer R Bethard; Janice S Blum; Azizul Haque
Journal:  Int J Mol Sci       Date:  2022-01-19       Impact factor: 5.923

6.  Protective Effects of Estrogen via Nanoparticle Delivery to Attenuate Myelin Loss and Neuronal Death after Spinal Cord Injury.

Authors:  Azizul Haque; Kelsey P Drasites; April Cox; Mollie Capone; Ali I Myatich; Ramsha Shams; Denise Matzelle; Dena P Garner; Mikhail Bredikhin; Donald C Shields; Alexey Vertegel; Naren L Banik
Journal:  Neurochem Res       Date:  2021-07-16       Impact factor: 3.996

7.  Anticancer Activity of Ganoderic Acid DM: Current Status and Future Perspective.

Authors:  John Matthew Bryant; Mollie Bouchard; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2017-12-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.